Skip to main
SRPT

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 26 analyst ratings
Hold
Strong Buy 12%
Buy 27%
Hold 46%
Sell 4%
Strong Sell 12%

Bulls say

Sarepta Therapeutics Inc. has reported a consistent number of start forms, with management expressing optimism for an inflection point in growth that could propel annual sales beyond the $500 million mark. The preliminary fourth-quarter 2025 net revenue of $259.2 million represents a 9% increase from the previous quarter, reflecting stable adoption of the company's products, while the revenue from its ELEVIDYS treatment reached $110.4 million, suggesting a significant potential run-rate of approximately $442 million annually. Positive initial data from ongoing Phase 1/2 programs in FSHD and DM1 could present additional growth opportunities, bolstered by favorable feedback from key opinion leaders regarding ELEVIDYS’s risk/benefit profile for both ambulatory and non-ambulatory patients.

Bears say

Sarepta Therapeutics Inc. faces a challenging financial outlook due to lower-than-expected preliminary net revenue for its product Elevidys in the fourth quarter of 2025, which fell short of consensus estimates. The company has highlighted concerns regarding revenue volatility, as the postponement of treatment for just a few patients significantly impacts quarterly results, indicating fragility in product demand. Furthermore, ongoing questions about Elevidys's efficacy and safety profile, combined with the emergence of competitive therapies that may provide better benefit-risk balances, contribute to a negative sentiment around the company's future financial stability.

Sarepta Therapeutics (SRPT) has been analyzed by 26 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 27% recommend Buy, 46% suggest Holding, 4% advise Selling, and 12% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Hold based on their latest research and market trends.

According to 26 analysts, Sarepta Therapeutics (SRPT) has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.